Fuminori Ito1, Naoto Furukawa2. 1. Department of Obstetrics and Gynecology, Nara Medical University, Nara, Japan. 2. Department of Obstetrics and Gynecology, Nara Prefecture Western Medical Center, 1-14-16 Mimuro, Sango-cho, Ikoma-gun, Nara, 636-0802, Japan. furunao0813@gmail.com.
Abstract
PURPOSE: There is no positive evidence for the efficacy of antiemetic triplet therapy with aprepitant (APR), palonosetron (PALO), and dexamethasone (DEX) for moderate emetogenic chemotherapy, especially for gynecologic malignancies. Thus, the present study evaluated the efficacy of this triplet therapy in patients receiving carboplatin and paclitaxel (CP) for gynecologic malignancy. METHODS: Seventy patients with gynecologic cancer receiving CP were enrolled into a prospective single-arm study with APR (125 mg on day 1, 80 mg on days 2-3), PALO (0.75 mg), and DEX (20 mg) before initiating chemotherapy. The primary endpoint was delayed complete response (CR) rate, i.e., no vomiting and no rescue, at 24-120 h after chemotherapy administration. RESULTS: Seventy patients were enrolled. The delayed CR rate was 97.1% (68/70). No serious adverse events were observed. Younger patient age (≤50 years) tended to be associated with a poor delayed CR rate. CONCLUSIONS: This study demonstrated a notable efficacy of antiemetic triplet therapy with APR, PALO, and DEX in female patients receiving CP. Further evaluation with a larger phase III trial is warranted.
PURPOSE: There is no positive evidence for the efficacy of antiemetic triplet therapy with aprepitant (APR), palonosetron (PALO), and dexamethasone (DEX) for moderate emetogenic chemotherapy, especially for gynecologic malignancies. Thus, the present study evaluated the efficacy of this triplet therapy in patients receiving carboplatin and paclitaxel (CP) for gynecologic malignancy. METHODS: Seventy patients with gynecologic cancer receiving CP were enrolled into a prospective single-arm study with APR (125 mg on day 1, 80 mg on days 2-3), PALO (0.75 mg), and DEX (20 mg) before initiating chemotherapy. The primary endpoint was delayed complete response (CR) rate, i.e., no vomiting and no rescue, at 24-120 h after chemotherapy administration. RESULTS: Seventy patients were enrolled. The delayed CR rate was 97.1% (68/70). No serious adverse events were observed. Younger patient age (≤50 years) tended to be associated with a poor delayed CR rate. CONCLUSIONS: This study demonstrated a notable efficacy of antiemetic triplet therapy with APR, PALO, and DEX in female patients receiving CP. Further evaluation with a larger phase III trial is warranted.
Entities:
Keywords:
Aprepitant; Chemotherapy-induced nausea and vomiting; Paclitaxel and carboplatin; Palonosetron
Authors: K Suzuki; T Yamanaka; H Hashimoto; Y Shimada; K Arata; R Matsui; K Goto; T Takiguchi; F Ohyanagi; Y Kogure; N Nogami; M Nakao; K Takeda; K Azuma; S Nagase; T Hayashi; K Fujiwara; T Shimada; N Seki; N Yamamoto Journal: Ann Oncol Date: 2016-06-29 Impact factor: 32.976
Authors: M S Aapro; S M Grunberg; G M Manikhas; G Olivares; T Suarez; S A Tjulandin; L F Bertoli; F Yunus; B Morrica; F Lordick; A Macciocchi Journal: Ann Oncol Date: 2006-06-09 Impact factor: 32.976
Authors: M Tanioka; A Kitao; K Matsumoto; N Shibata; S Yamaguchi; K Fujiwara; H Minami; N Katakami; S Morita; S Negoro Journal: Br J Cancer Date: 2013-07-16 Impact factor: 7.640
Authors: Lee Schwartzberg; Sally Y Barbour; Gary R Morrow; Gianluca Ballinari; Michael D Thorn; David Cox Journal: Support Care Cancer Date: 2013-10-19 Impact factor: 3.603